BioNTech AG has appointed Özlem Türeci as chief medical officer to oversee its portfolio of individualised therapies for cancer. She has chaired BioNTech’s scientific and clinical advisory board since the company’s founding in 2008.
Dr Türeci was previously co-founder and chief executive of Ganymed Pharmaceuticals, a drug developer that was acquired by Astellas Pharma Inc in 2016. She is an executive board member of the Association for Cancer Immunotherapy and chair of the German Cluster Initiative of Individualized ImmunIntervention, both in Mainz, Germany.
BioNTech announced the appointment on 29 May 2018.
Copyright 2018 Evernow Publishing Ltd